Dr. Madina Karimova appointed head of new Transgenic Core Facility department beginning October 2016
| The Transgenic Core Facility (TCF) department, which has been established as a new central unit at Georg-Speyer-Haus, serves as the new hub handling all issues in transgenic and CRISPR/Cas9 technology under the leadership of Dr. Madina Karimova.
The TCF is expected to constitute a state-of-the-art platform for the development of transgenic mouse models and precise genome editing technologies (CRISPR/Cas9) to better understand human diseases. New mouse models can be generated as direct or conditional knock-out, knock-in or point mutations. Various techniques will be applied for this purpose such as microinjection of DNA and CRISPR/Cas9 components or blastocyst injection. The TCF is the central service facility for both researchers of the Georg-Speyer-Haus and external research groups.
Under the leadership of Dr. Madina Karimova, the Transgenic Core Facility working group will focus on the development of innovative genome modifications to address an increasing complexity of disease models and to enable therapeutic approaches. The focus is to develop rational enzymes and genetic strategies that are highly specific to the genomic locus (safe) and robust in mediating the desired DNA modification (efficient). Special emphasis is placed on safe Cre/LoxP-like recombinases and CRISPR/Cas9 technologies.
About Dr. Madina Karimova
Dr. Madina Karimova (30) studied microbiology at Kazan Federal University (Russia). She wrote her PhD thesis in the lab of Prof. Dr. Frank Buchholz at the Max Planck Institute of Molecular Biology and Genetics in Dresden on Novel site-specific recombinases for genome engineering and received Magna Cum Laude for her dissertation in 2012. As a postdoctoral fellow in the lab of Prof. Frank Buchholz, Dr. Karimova developed novel enzymes that were patented. She then worked at the Heinrich Pette Institute, Leibniz Institute for Experimental Virology in Hamburg in the laboratory of Prof. Dr. Joachim Hauber as a postdoctoral fellow. For the last two years, Dr. Karimova has been working in the Transgenic Department and Cellular Reagents, Innovation Medicines at AstraZeneca in Gothenburg, Sweden as a Senior Research Scientist.
Institute for Tumor Biologie and
60596 Frankfurt am Main
Click here for more news rund um das GSH in unserem Newsroom.